Take stock of 25 authorized cooperation in the first half of the year Consino, Tianshili and other companies to introduce which innovative drugs.

The introduction of products from the outside has become one of the important ways for pharmaceutical companies to expand their product pipelines.
information shows that in the first half of 2020 China's biopharmaceutical sector licensed trading cooperation remains active.
According to incomplete statistics, at least 25 Chinese pharmaceutical companies introduced innovative therapies from outside China in the first half of the year, including Beda Pharmaceuticals, Concino, Tianshili, Howson Pharmaceuticals, Redding Pharmaceuticals, Xinda Bio, Fosun Pharmaceuticals, Baiji Shenzhou and other companies.
this article, we've selected some of the high-profile licensing collaborations to see what innovative products and technologies these star companies have introduced.
2020 China Company Authorized Trading Cases (Anthost) Note: This table is incomplete statistics.
source: company press releases and public information.
statistical period: 2020/1/1-2020/6/30.
pharmaceutical mission map 1, the new coronavirus vaccine affected by the new crown outbreak, the vaccine used to prevent the new coronavirus infection (COVID-19) became one of the focus of the first half of the cooperative transaction.
, Fosun Pharma acquired an exclusive development and commercial interest in CoviD-19 vaccine products from BioNTech in Greater China (Chinese mainland, Hong Kong, Macau and Taiwan) in a deal valued at $85 million.
recently, Fosun Pharma announced that bioNTech-licensed mRNA vaccine BNT162b1 has been approved for clinical research in China, intended to be developed mainly for the prevention of new coronavirus infections in people aged 18 and over.
, a number of Chinese companies have also reached cooperation in the development of new coronavirus vaccines or antibodies.
For example, Concino Bio and Canada's Precision NanoSystems (PNI) have reached an agreement to develop a new coronavirus vaccine based on mRNA lipid nanoparticle (mRNA-LNP) technology using PNI's unique RNA vaccine technology platform, and Concino Bio will be given the right to promote vaccine products in Asia (excluding Japan).
addition, and Platinum Pharmaceuticals, Regency Bio, Clover Biology, Ai Weixin and other companies have reached a different company on the new coronavirus vaccine or antibody cooperation.
2, lysovirus therapy lysovirus is a class of viruses that can effectively infect and eliminate cancer cells.
lysovirus immunotherapy has a dual anti-cancer mechanism: they can not only cause cancer cell cleavage death through the infection of lysovirus infection into the tumor, but also can express tumor-specific immune activation protein, stimulate the systemic anti-tumor immune response.
, lysoviral therapy has become an important research field in the field of tumor immunotherapy.
first half of this year, Chinese companies, including Tiansli and Pumis Bio, introduced lysovirus in their research products.
: A lysovirus product, C-REV, was introduced from Japan's Takara Bio for a total down payment and milestone payment of up to $27.5 million.
C-REV is a type 1 herpes simplex virus (HSV-1) reduced strain that selectively replicates and breaks down tumor cells in tumor cells without damaging normal cells.
, C-REV is being developed to treat pancreatic cancer and melanoma.
: In a slight partnership with Finland's TLT Biotherapeutics, it has acquired a development and commercial interest in TLT-123, one of its lysovirus products, in Greater China.
TLT-123 is a human 5/3 chimed adenovirus that can only selectively replicate and dissolve tumors in most human tumor cells.
addition, the product is expected to further improve the role of anti-tumor therapy by expressing immunomodulation cytokines in the tumor, without causing an increase in toxic side effects.
3, dual-specific antibody biseteric antibody because it contains two specific antigen binding points, can interact with both target cells and functional cells (such as T-cells), mediate a series of immune responses, favored by enterprises.
, according to public information, in the first half of the year, a number of Chinese companies introduced dual-specific antibodies in the study of drugs, including Reding Pharmaceuticals, Genesis and other companies.
Reeding Pharmaceuticals: Regeneron acquired an exclusive commercial interest in the development and exclusive commercialization of regeneron, a dual-specific antibody, reGENeron, in Greater China for up to $190 million.
REGN1979 is designed to kill cancer cells by binding to B-cell tumor proteins (CD20) and immune system T-cells (CD3).
the drug has been approved by the FDA as an orphan drug for the treatment of diffuse large B-cell lymphoma (DLBCL) and fable lymphoma (FL).
, REGN 1979 clinical trial applications were accepted in July this year.
Genesis: A global strategic partnership with Affibody has resulted in exclusive development and commercialization rights to ABY-035, an autoimmune innovation drug, in countries and regions such as Greater China and South Korea, as well as the right to conduct clinical development in the Asia-Pacific region outside Japan, with a down payment and milestone payment of up to $225 million.
ABY-035 is a new dual-specific molecule developed by Affibody using its original technology platform, which can specifically bind two sub-base of IL-17A and albumin in the serum, and is about to complete phase 2 clinical trials across the world for patients with psoriasis.
ABY-035 has the characteristics of very small molecular weight, higher affinity and half-life similar to monoantigen compared to traditional antibody drugs.
addition to the introduction of products, there are a number of companies in the field of dual-specific antibodies also reached research and development cooperation.
, Cyntaf and Roche reached a strategic partnership to develop and commercialize multiple dual-specific antibodies and cell therapy products.
will be responsible for product development, production and commercialization, while Roche reserves exclusive repurchase options for development and commercialization interests in these products outside of China.
if Roche exercises all of its options, a down payment and milestone payment totalling approximately $21 will be made to Xinta Bio.
4, monoclonal antibody drug monoclonal antibody is still one of the hot topics of enterprise research.
the first half of this year, companies including Beda Pharmaceuticals, Lakai Pharmaceuticals, Xinda Bio, Baiji Shenzhou, etc. introduced different types of monoclonal antibodies, including PD-1/PD-L1 antibodies, CTLA-4 antibodies, CD47 subject antibodies and so on.
, Bayda Pharmaceuticals signed a $35 million partnership with Agenus to introduce the latter's PD-1 antibody balstilimab and CTLA-4 antibody zalifrelimab, two tumor immuno monoclonal antibodies.
Pharmaceuticals acquired the exclusive global rights to a PD-L1 antibody (FAZ053) from Novartis.
Xinda Bio has been awarded a development and commercialization interest in Aledctor's antibody (AL008) targeting SIRP-alpha (CD47 subject).
has introduced three monoclonal antibody drugs, including stuximab beta, and single resistance to Dickkopf-1 (DKK1).
addition to the above-mentioned drug types, other imported products include CDK4/6 inhibitors, peptide drugs, antiviral drugs, stem cell drugs, BTK inhibitors and so on.
Information and Public Information of the companies.
.